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Summary
Background: The goal of this study was to conduct an accelerated vaccination program and to
determine its efficacy in patients susceptible to hepatitis B virus (HBV) receiving chemotherapy
because of their hematologic malignancies.
Methods: Over a one-year period, a total of 327 patients who were diagnosed as having a
hematologic malignancy were serologically analyzed in terms of HBV infection. Of those found to
be susceptible to HBV infection, a total of 42 patients consisting of 16 females and 26 males were
enrolled in the accelerated vaccination program. All the patients were administered a 20-mg
yeast-derived recombinant hepatitis B vaccine on days 0, 14, and 28. Anti-HBs titers above 10 IU/l
at 1 and 3 months after the final dose were accepted as protective.
Results: A total of 146 (44.6%) patients were susceptible to HBV, while 13 (4.0%) were carriers, 28
(8.6%) were vaccinated, and 113 (34.5%) had had a previous HBV infection. A total of 42 patients
(16 females and 26males, mean age 34.5  10.9 years) were enrolled in the vaccination program.
Overall, 23.8% (10/42) of the patients in the program had developed anti-HBs at one month after
the last vaccination.
Conclusions: Poor results obtained by different vaccination programs suggest the need for alter-
native strategies to prevent the disease.
# 2007 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.* Corresponding author. Tel.: +90 232 390 45 10;
ax: +90 232 373 45 38.
E-mail address: husnup@yahoo.com (H. Pullukcu).
201-9712/$32.00 # 2007 International Society for Infectious Diseases.
oi:10.1016/j.ijid.2007.06.004Introduction
In patients with a hematologic malignancy, a newly devel-
oping infection of hepatitis B virus (HBV) results in the
interruption of chemotherapy for a long period, in conjunc-Published by Elsevier Ltd. All rights reserved.
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Table 1 Distribution of patients according to diagnosis and
gender
Diagnosis Male Female Total
Non-Hodgkin lymphoma 53 34 87
Acute myelocytic leukemia 38 39 77
Multiple myeloma 33 32 65
Hodgkin lymphoma 15 12 27
Acute lymphocytic leukemia 15 10 25
Mycosis fungoides 8 7 15
Myelodysplastic syndromes 6 4 10
Hairy cell leukemia 6 1 7
Chronic lymphocytic leukemia 2 5 7
Chronic myelocytic leukemia 5 1 6
Acute leukosis 1 - 1
Total 182 145 327tion with disruption in the management of the primary
condition; consequently this results in difficulties in control-
ling the malignant condition. Patients with a weakened
immune system due to chemotherapy develop a more severe
clinical picture, which in turn yields to the development of
chronic hepatitis B at high rates.1—5
HBV reactivation is a described complication in cancer
patients who receive cytotoxic chemotherapy, and may
result in varying degrees of liver damage.6 As chemotherapy
is used increasingly in cancer patients, HBV reactivation
during cytotoxic treatment may become a more common
problem. Lok et al. reported that 26% of lymphoma patients
had chronic HBV infection and 47% of them developed HBV
reactivation during chemotherapy, which resulted in a 5%
mortality.7 In another study, it was stated that while the
incidence of chronic HBV was 18% in patients with a hema-
tologic malignancy, the acute exacerbation rate was 37.5% in
HBV carriers.8 Pinto et al. reported acute exacerbation in five
patients with hematologic malignancy and HBV infection, and
four of them died.9 Studies conducted on adult patients with
hematologic malignancies show that HBV carrier status
reaches rates of over 20% in our country.10,11 HBV carriers
have the risk of fatal HBV exacerbation during chemother-
apy/radiotherapy.10—14
In HBV reactivation, two possible mechanisms may be
involved. While immunosuppression during chemotherapy
may allow enhanced HBV replication and thereby lead to
direct hepatic toxicity, the overt exacerbation of hepatitis is
more likely to be a result of a rebound immune response. The
latter is explained by the fact that the administration of
immunosuppressive agents results in T lymphocyte deple-
tion, and this suppresses the normal immunological response
to viral antigens and allows widespread infection of hepato-
cytes.8,14,15
In patients with a diagnosis of hematologic malignancy,
chemotherapy is introduced at the earliest period in order to
achieve an early remission. This is the period in which the
patients are most susceptible to HBV infection. Hence, the
determination of HBV status at the time of diagnosis of the
malignancy and the immunization of susceptible subjects
with an active vaccination schedule is of crucial importance.1
The goal of this study was to search for the indicators of
HBV infection, to conduct an accelerated vaccination pro-
gram on the susceptible patients, and to determine the
efficacy of vaccination in patients receiving chemotherapy
because of their hematologic malignancies.
Materials and methods
The study group
Three hundred and twenty-seven patients who had been
followed up for various hematologic malignancies between
April 2003 and April 2004 were prospectively included in the
study. The study was started with the approval of the local
ethics committee. Informed written consent was obtained
from each patient. Patients were grouped according to the
results of HBV serologic marker testing. HBV carriers,
patients who had previously had the infection, those who
had previously been vaccinated, and patients with an iso-
lated anti-HBc positivity were excluded. The clinical condi-
tion of each patient was evaluated by the EasternCooperative Oncology Group (ECOG) performance status
scoring system, and those with an ECOG score over three
were excluded from the study.16 There was no plan for an
autologous/allogeneic bone marrow transplantation for any
of them within the next month.
Serologic examinations
A blood specimen of 10 ml was taken from each patient in
order to perform the serologic tests for HBV (HBsAg, anti-HBc
total, and anti-HBs). All of the HBV markers were studied
using enzyme immune assays (HBsAg IEMA WELL, anti-HBs
IEMAWELL, anti-HBc EIAWELL; Radim, Rome, Italy). A 20-mg
recombinant hepatitis B vaccine derived from yeast cells was
administered to each patient on days 0, 14, and 28 (a total of
three doses) by intramuscular route into the deltoid muscle.
One and three months after the last dose of vaccine, HBV
markers were re-examined to search for the emergence of
anti-HBs, and also to detect the development of a possible
acute HBV infection. Anti-HBs levels were assayed through
titrimetric analyses, and titers >10 IU/l were accepted as
protective. Throughout the study period, all patients had
normal liver function test values.
Statistical analysis
Data obtained were recorded and evaluated in SPSS 11.0
package program. Fisher’s exact and Chi-square tests were
used for statistical comparisons.
Results
The primary diagnoses and HBV status characteristics of the
327 patients (182 male and 145 female, mean age
48.4  17.4 years) are shown in Tables 1 and 2.
Forty-two of the 146 HBV sensitive patients accepted
enrollment in the vaccination program (16 female and 26
male, mean age 34.5  10.9 years; Table 3). All of the
patients were receiving chemotherapy. The patients’ aver-
age ECOG score was 1.5  0.7 (one patient got 0 points, 22
patients got 1 point, 15 patients got 2 points, and four
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Table 2 HBV status by patient age and gender
Age groups Female Male Total
15—20 21—30 31—40 41—50 51—60 >60 Female total 15—20 21—30 31—40 41—50 51—60 >60 Male total
Sensitive 4 6 12 11 12 13 58 8 16 12 16 18 18 88 146 (44.6%)
Carrier 1 2 2 1 1 7 1 2 2 1 6 13 (4.0%)
Vaccinated 3 2 2 3 4 14 3 2 1 4 2 2 14 28 (8.6%)
Past infection 3 3 8 13 11 14 52 4 5 7 16 11 18 61 113 (34.5%)
IaHBc positivitya 2 3 3 6 14 1 1 1 5 5 13 27 (8.3%)
Total 11 11 24 31 30 38 145 15 25 23 37 38 44 182 327
a IaHBc: isolated anti-HBc positivity.
Table 3 Distribution of age, gender, and clinical diagnosis for the patients enrolled in the vaccination program
Clinical diagnosis Female Male Total
Age Female total Age Male total
15—20 21—30 31—40 41—50 51—60 15—20 21—30 31—40 41—50 51—60
Non-Hodgkin lymphoma 4 1 1 6 2 3 2 1 8 14
Acute myelocytic leukemia 1 1 1 3 2 1 1 4 7
Hodgkin lymphoma 1 1 2 2 2 4 6
Multiple myeloma 1 1 1 2 1 4 5
Acute lymphocytic leukemia 1 1 1 3 1 1 4
Chronic myelocytic leukemia 1 2 3 3
Chronic lymphocytic leukemia 1 1 1
Hairy cell leukemia 1 1 1
Myelodysplastic syndromes 1 1 1
Total 2 3 6 3 2 16 2 8 8 7 1 26 42
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nation program.
Overall, 23.8% (10/42) of the patients in the program had
developed >10 IU/l anti-HBs at one month after the last
vaccination (two with non-Hodgkin lymphoma, two with
acute myelocytic leukemia, one with multiple myeloma,
one with Hodgkin lymphoma, two with acute lymphocytic
leukemia, one with a myelodysplastic syndrome, and one
with chronic lymphocytic leukemia). Antibody production
was detected in 43.7% (7/16) of the female patients and
in 11.5% (3/26) of the males ( p = 0.035). Titrimetric anti-HBs
values ranged between 10 and 100 IU/l.
Due to a decrease in antibody titers (to<10 IU/l), 19.0% of
the patients were anti-HBs positive at the third month
following the last vaccination.
When questioned about any adverse effects of the vac-
cine, no serious side effect was notified except for local pain
in the arm where the vaccine was applied. None of the
patients developed an acute HBV infection throughout the
vaccination and follow-up period.
Discussion
Patients with hematologic malignancies are at risk for HBV
infection not only due to the immunodeficiency arising as a
result of the primary disease and bone marrow suppression
secondary to chemotherapy and radiotherapy, but also due to
the frequent blood transfusions and interventional proce-
dures employed. Since our country is an intermediate ende-
mic region for HBV infection and high rates of horizontal
transmission are being observed, it has become necessary to
study this particular patient group.1,17
A wide range of studies conducted in our country on
healthy adults and children have shown the rates of HBV
carrier status ranging between 3.9% and 12.5%.18 In studies
designed to detect the HBV seroprevalence among patients
with hematologic malignancies, rates of carrier status among
children have been found to range between 6% and 57.2%,
whereas rates among adults have been found to range
between 6% and 40.6%.1,2,18,19 Anti-HBs positivity rates in
the same adults have been detected between 31.4% and
33.3%.1,2,18,19 The rates reported in these studies are similar
to those reported for healthy individuals. However it is also
known that there is not much difference in HBV infection
rates between the risk groups such as, healthcare workers,
dialysis patients, etc., and the normal population in moder-
ately or highly endemic areas.20 In our study, the carrier
status rate in 327 patients with a hematologic malignancy
was detected as 4%. When HBsAg, anti-HBc, and anti-HBs
markers were also considered, the exposure rate to HBV
reached 46.5%.
The overall anti-HBs positivity rate was 23.8% at the end of
our accelerated vaccination program. Antibody production
was detected in 43.7% of the female patients and in 11.5% of
the male patients. In vaccination studies conducted in
healthy adults, it has been recognized that women develop
antibody responses in higher titrations than men.21—23 Three
months after the vaccination program, anti-HBs titers in one
male and one female patient decreased below detection
limits. Pressure on immunity in these patients can cause
the antibody titers determined at the beginning to fall under
the levels to be determined later on.To our knowledge, no accelerated hepatitis B vaccination
study conducted on adult patients with hematologic malig-
nancies exists. This has brought difficulties in the interpreta-
tion of our results. There are various publications analyzing
the efficacy of different vaccination programs on pediatric
patients receiving chemotherapy due to their hematologic
malignancies. It has been reported in India that in children
and young adults, anti-HBs seroconversion rates are between
19% and 36%.24,25 In our country, Yetgin et al. achieved an
anti-HBs positivity rate of 35% in children with hematologic
malignancies, following a vaccination program in which
increased numbers of doses (each being 20 mg) were admi-
nistered.26 In a study from our region including 36 pediatric
cases with different malignancies, an anti-HBs seroconver-
sion rate of 61% was obtained after the application of seven
double-dose vaccines. In this study, it was reported that the
antibody response was obtained in all of the patients who had
received maintenance chemotherapy.27 Our vaccination pro-
gram appears to bemore advantageous owing to the ability to
attain a quick antibody response.
During the study period, liver function tests were carried
out twice weekly on a regular basis. No clinical and serologic
acute HBV infection was detected in the patients. In an
earlier study, despite active immunization, acute hepatitis
B infection was reported to develop in 5.6% of patients who
had failed to show anti-HBs seroconversion.27 The low ser-
oprevalence of hepatitis B in our region may have played a
partial role in this phenomenon.18 Regarding the presence of
HBV carrier status in up to 20% in the eastern regions of our
country, we consider that if similar studies were conducted in
these regions on patients with hematologic malignancies,
even higher rates of HBV exposure would have been
detected. Likewise, in India, Goyal et al.24 reported that
HBV developed in 48% of patients who had been taken into a
vaccination program during remission induction therapy, and
Somjee et al.25 reported a 43% HBV occurrence rate in their
patients.
Each day, new chemotherapy regimens are introduced
for the management of patients with hematologic malig-
nancies and for patients with other solid tumors. With
these new therapies we can predict that the survival rates
of these patients will even increase in the near future.
Moreover, in recent years, a rapid increase has been
observed in the number of immunocompromised patients
due to conditions such as transplantation and HIV positivity.
This results in the formation of a high-risk group for HBV
infection. In the light of this fact, it has been understood
that vaccination studies against HBV infection in immuno-
compromised patients will become even more important in
the forthcoming years.
In conclusion, the high prevalence of HBV infection in
patients with hematologic malignancies and the poor results
obtained from different vaccination programs suggest the
need for alternative strategies to prevent the disease. We
believe that active immunization combined with hepatitis B
immunoglobulin given simultaneously may yield better
response rates and reduce the endemicity of HBV infection
in this particular group of patients. Therefore, further stu-
dies aimed at investigating the role and effectiveness of
combined immunoprophylaxis regimens on wider groups with
longer follow-up periods are needed.
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